Scholarlink

<p>Excessive activation of the immune system by damage-associated molecular patterns (DAMPs) contributes to COVID-19 severity. Interferon-induced protein 35 (IFI35) is a DAMP-related interferon-stimulated gene recently proposed as a biomarker of hyperinflammation. We investigated the association between IFI35 serum levels, gene expression, and COVID-19 severity in 430 hospitalized patients (214 critical and 216 severe) and 112 convalescent controls. Serum IFI35 levels were quantified using ELISA, and IFI35 mRNA expression in PBMCs was assessed using quantitative PCR (qPCR). IFI35 levels were significantly higher in critically ill patients (median 1,003.6 pg/mL) than in severe cases (867.6 pg/mL; <i>p</i> = 0.001) and controls (798.3 pg/mL; <i>p</i> &lt; 0.0001). Gene expression analysis showed a similar pattern (<i>p</i> = 0.014). Higher IFI35 levels were also associated with adverse clinical outcomes, including mortality, invasive mechanical ventilation, acute kidney injury, and cardiac arrest (all <i>p</i> &lt; 0.05). In receiver operating characteristic analysis, adding IFI35 to a model including C-reactive protein and D-dimer improved discriminative performance for mortality. In survival analysis, IFI35 &gt; 1,475 pg/mL was associated with reduced survival in this cohort (<i>p</i> = 0.0062). These findings identify IFI35 as a promising prognostic biomarker associated with COVID-19 severity and adverse outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interferon-induced protein 35 (IFI35) is associated with COVID-19 severity and clinical outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Mariana Ramos Freitas,
  • Chirles Araújo de França,
  • Sávio Luiz Pereira Nunes,
  • Milena Xavier Barbosa,
  • Carlos Dornels Freire de Souza,
  • Anderson da Costa Armstrong,
  • Rodrigo Feliciano Carmo

摘要

Excessive activation of the immune system by damage-associated molecular patterns (DAMPs) contributes to COVID-19 severity. Interferon-induced protein 35 (IFI35) is a DAMP-related interferon-stimulated gene recently proposed as a biomarker of hyperinflammation. We investigated the association between IFI35 serum levels, gene expression, and COVID-19 severity in 430 hospitalized patients (214 critical and 216 severe) and 112 convalescent controls. Serum IFI35 levels were quantified using ELISA, and IFI35 mRNA expression in PBMCs was assessed using quantitative PCR (qPCR). IFI35 levels were significantly higher in critically ill patients (median 1,003.6 pg/mL) than in severe cases (867.6 pg/mL; p = 0.001) and controls (798.3 pg/mL; p < 0.0001). Gene expression analysis showed a similar pattern (p = 0.014). Higher IFI35 levels were also associated with adverse clinical outcomes, including mortality, invasive mechanical ventilation, acute kidney injury, and cardiac arrest (all p < 0.05). In receiver operating characteristic analysis, adding IFI35 to a model including C-reactive protein and D-dimer improved discriminative performance for mortality. In survival analysis, IFI35 > 1,475 pg/mL was associated with reduced survival in this cohort (p = 0.0062). These findings identify IFI35 as a promising prognostic biomarker associated with COVID-19 severity and adverse outcomes.